SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is experiencing a surge, driven by factors like potential Fed rate cuts and renewed focus from Elon Musk. Community discussions revolve around the stock potentially reaching $400 soon, with some anticipating a gamma squeeze. Others caution about overvaluation and potential pullbacks, highlighting the stock's volatile nature.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amid heated discussions and political rhetoric following a shooting involving conservative activist Charlie Kirk. The community is divided, with some users trading accusations related to political affiliations and alleged radicalization, while others are focusing on the Epstein files and calling for their release. Broader discussions touch upon gun control, media influence, and the state of political discourse.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community anticipates a potential ETF launch, though some traders suggest the launch may be delayed. Bullish sentiment is fueled by speculation of increased institutional investment, with some setting targets and calling for a push to new highs. Despite the optimism, some traders caution against a potential "sell the news" event.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

ATYR is trending due to anticipation surrounding upcoming data release for their Phase 3 trial, with community members actively discussing potential outcomes and comparing the situation to previous short squeeze events like GME. Bullish sentiment centers around the belief in positive data and a potential short squeeze, while bears, including figures like Martin Shkreli, express skepticism and anticipate a negative outcome. The discussion includes technical analysis, potential price targets, and the overall risk/reward profile of this binary event.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending due to a recent $20 million investment agreement, sparking discussions about potential market capitalization changes and future news catalysts. The community is actively debating the implications of this investment, alongside speculation about upcoming events and their effect on the stock's price. Some traders are also highlighting the stock's low float and high short interest as potential drivers for significant price movement.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna's stock is trending downwards amid reports linking COVID-19 vaccines to child deaths and Trump administration scrutiny, sparking concerns about the company's future and government contracts. The community is actively discussing potential manipulation and corruption, while some view the dip as a buying opportunity or anticipate a short squeeze. Despite the negative news, some are optimistic about Moderna's pipeline beyond COVID-19 and its potential in AI-driven cancer treatments.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to regulatory clearance for its Oxford Ionics acquisition, sparking discussions about the deal's implications and potential synergies. Community members are debating whether the stock is overvalued and if it can maintain its gains, while also weighing the broader prospects of the quantum computing sector. Some traders are eyeing shorting opportunities, while others express bullish sentiment, anticipating further catalysts.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending amid discussions around potential links between COVID vaccines and child deaths, sparking debates over vaccine safety and potential liabilities. The community is weighing the impact of these concerns against the broader context of Pfizer's pipeline and dividend yield, with some calling for leadership changes. Some are considering the potential rotation to big pharma as the market corrects.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amid speculation of a potential takeover bid by Paramount Skydance, sparking significant trading volume and price movement. Community discussions revolve around potential bidding wars, valuation estimates, and the possibility of a deal announcement soon. Some investors are expressing concerns around debt and potential shareholder impact, while others are optimistic about a potential bidding war.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

CRCL is trending downwards, sparking debate about its valuation, especially as insiders sell shares and rate cuts loom, potentially impacting revenue. The community is discussing whether it can hold key support levels, or if it will continue its descent towards its IPO price, while new stablecoin competition adds to bearish sentiment. Some traders see potential for short-term gains, while others remain convinced of a longer-term decline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline 

Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.

Shares of Tourmaline Bio (TRML) jumped 58% in the pre-market session on Tuesday after Novartis (NVS) announced that it has agreed to acquire the smaller biopharmaceutical firm.Under the <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novartis.com/news/media-releases/novartis-acquire-tourmaline-bio-complementing-cardiovascular-pipeline-pacibekitug-treatment-atherosclerotic-cardiovascular-disease-ascvd">deal</a>, Novartis will commence a tender offer to purchase all outstanding shares of Tourmaline common stock through an indirect wholly owned unit. The deal price of $48 per share presents a premium of nearly 59% to Tourmaline’s last closing price and values the company at about $1.4 billion on a fully diluted basis. Following the closing of the tender offer, the unit will merge with Tourmaline, and the company will become an indirect wholly owned subsidiary of Novartis.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TRML">TRML stock</a> jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.Meanwhile, sentiment around <a href="https://stocktwits.com/symbol/NVS">NVS stock</a> fell from ‘Neutral’ to ‘Bearish territory, while message volume rose from ‘low’ to ‘normal’ levels.Novartis stated that the acquisition includes Tourmaline’s Pacibekitug being developed as a treatment option for atherosclerotic cardiovascular disease or the build-up of fats, cholesterol, and other substances in and on the artery walls. Pacibekitug complements Novartis’ cardiovascular strategy, the company said, while noting that with mid-stage trials of Pacibekitug already well-advanced, the company will acquire a late-stage-ready asset."Inflammation is a major driver of cardiovascular disease, and the team at Tourmaline has made significant progress with this asset. We are excited to bring Pacibekitug into the Novartis portfolio and collaborate with the Tourmaline team to advance its development as we diversify our efforts in cardiovascular care," said Shreeram Aradhye, Chief Medical Officer of Novartis. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; The transaction has been unanimously approved by the Board of Directors of both companies. It is expected to close in the fourth quarter of 2025, subject to the satisfaction or waiver of customary closing conditions. Until the transaction is closed, the two companies will continue to operate as separate, independent entities, Novartis said.TRML stock is up by 49% this year, while NVS stock gained over 32%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-launches-ai-machine-learning-platform-called-tunelab/chwKTzARdsU">Eli Lilly Launches AI, Machine Learning Platform Called TuneLab For Biotech Companies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Tourmaline Bio Stock Just Rocketed 58% Pre-Market – Here’s What Happened

Novartis has announced that it has agreed to acquire the biopharmaceutical firm, and the deal price of $48 per share presents a premium of nearly 59% to Tourmaline’s last closing price. 

Equity

Novartis has announced that it has agreed to acquire the biopharmaceutical firm, and the deal price of $48 per share presents a premium of nearly 59% to Tourmaline’s last closing price. 


Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's  What You Should Know

The consensus price target hints at a 151% upside potential for Tourmaline Bio, Inc. (TRML). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Tourmaline Bio (TRML) Receives a Buy from Piper Sandler

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Tourmaline Bio (TRML Research Report), with a price targ...

The Lustgarten Foundation Appoints Two New Board Members

The Lustgarten Foundation Appoints Two New Board Members The Lustgarten Foundation Appoints Two New Board Members PR Newswire WOODBURY, N.Y., June 13, 2024 Richard Barakat, MD, and Aaron Kantoff join...

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo's recent acquisition of...

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $55.60 Consensus Target Price from Analysts

Shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) have earned an average recommendation of "Buy" from the six analysts that are currently covering the firm, Marketbeat reports. Six...

Tourmaline Bio (NASDAQ:TRML) Price Target Increased to $72.00 by Analysts at Jefferies Financial Group

Tourmaline Bio (NASDAQ:TRML  Free Report) had its target price raised by Jefferies Financial Group from $41.00 to $72.00 in a report released on Wednesday morning, Benzinga reports. Jefferies...

Tourmaline Bio (NASDAQ:TRML) Shares Gap Down to $44.67

Tourmaline Bio, Inc. (NASDAQ:TRML  Get Free Report)s share price gapped down prior to trading on Thursday . The stock had previously closed at $44.67, but opened at $29.29. Tourmaline...

Q1 2024 Earnings Estimate for Tourmaline Bio, Inc. Issued By Leerink Partnrs (NASDAQ:TRML)

Tourmaline Bio, Inc. (NASDAQ:TRML  Free Report)  Equities researchers at Leerink Partnrs upped their Q1 2024 earnings per share estimates for shares of Tourmaline Bio in a research...

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. It offers the TOUR006. The company was founded by Sandeep Kulkarni on September 17, 2021 and is headquartered in New York, NY.

Tourmaline Bio Inc

Buying for a long-term investment

Buying for a short-term trade

Trading around the volatility

Avoiding it

$GEMI IPO day is upon us, how are you playing it?

Stocktwits

Gemini Space Station

 IPO day is upon us, how are you playing it?

TRML
Tourmaline Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TRML News

TRML Tourmaline Bio Inc